skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current therapeutic strategies for invasive and metastatic bladder cancer

Review

(1620) Views  (529) Full article downloads

Authors: Vishnu P, Mathew J, Tan WW

Published Date July 2011 Volume 2011:4 Pages 97 - 113
DOI: http://dx.doi.org/10.2147/OTT.S22875

Prakash Vishnu, Jacob Mathew, Winston W Tan
Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL, USA

Background: Bladder cancer is one of the most common cancers in Europe, the United States, and Northern African countries. Muscle-invasive bladder cancer is an aggressive epithelial tumor, with a high rate of early systemic dissemination. Superficial, noninvasive bladder cancer can most often be cured; a good proportion of invasive cases can also be cured by a combined modality approach of surgery, chemotherapy, and radiation. Recurrences are common and mostly manifest as metastatic disease. Those with distant metastatic disease can sometime achieve partial or complete remission with combination chemotherapy.
Recent developments: Better understanding of the biology of the disease has led to the incorporation of molecular and genetic features along with factors such as tumor grade, lympho-vascular invasion, and aberrant histology, thereby allowing identification of ‘favorable’ and ‘unfavorable’ cancers which helps a more accurate informed and objective selection of patients who would benefit from neoadjuvant and adjuvant chemotherapy. Gene expression profiling has been used to find molecular signature patterns that can potentially be predictive of drug sensitivity and metastasis. Understanding the molecular pathways of invasive bladder cancer has led to clinical investigation of several targeted therapeutics such as anti-angiogenics, mTOR inhibitors, and anti-EGFR agents.
Conclusion: With improvements in the understanding of the biology of bladder cancer, clinical trials studying novel and targeted agents alone or in combination with chemotherapy have increased the armamentarium for the treatment of bladder cancer. Although the novel biomarkers and gene expression profiles have been shown to provide important predictive and prognostic information and are anticipated to be incorporated in clinical decision-making, their exact utility and relevance calls for a larger prospective validation.

Keywords: bladder cancer, chemotherapy, biologic therapy, neoadjuvant, PI3kinase/mTOR pathway





 

Other articles by Dr Winston Tan



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Transcorneal electrical stimulation increases chorioretinal blood flow in normal human subjects
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Treatment of patients with von Willebrand disease
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer